Conference Coverage: ESMO 2022 – Focus on GU

Impact of recent ESMO data on clinical practice and therapy guidance in genitourinary cancer

September 16, 2022
Daniel Petrylak, MD, Yale, Aptitude Health

FACULTY CHAIR

Daniel Petrylak, MD

Yale Cancer Center, New Haven, CT, USA

Faculty Members

Susan Slovin, MD, PhD
Memorial Sloan Kettering Cancer Center, New York, NY, US

Leonard G. Gomella, MD, FACS
Sidney Kimmel Cancer Center, Philadelphia, PA, US

Robert Dreicer, MD, MACP, FASCO
University of Virginia Cancer Center, Charlottesville, VA, US

Scott Tagawa, MD, FACP
Weill Cornell Medicine, New York, NY, US

Thomas Powles, MD, MBBS, MRCP
Barts Cancer Centre, London, UK

Karim Fizazi, MD, PhD
Gustave Roussy Institute, Villejuif, France

José Pablo Maroto Rey, MD, PhD
Hospital de Sant Pau, Barcelona, Spain

Sample Report

Start discovering the insights

View Report

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

  • Localized and Metastatic Castration-Sensitive Prostate Cancer
  • Metastatic Castration-Resistant Prostate Cancer
  • Nonmuscle-Invasive Bladder Cancer and Muscle-Invasive Bladder Cancer
  • Locally Advanced and Metastatic Bladder Cancer
  • Renal Cell Carcinoma

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.